Clique on Dry Eye

MGD: Where are we Going?

Shane Swatts — Sat, 17 Aug 2024 07:51:00 +0000

Interview with Dr. Josh Johnston of Georgia Eye Partners. Dr. Johnston shares with us his tips and tricks for successful Meibomian Gland Dysfunction (MGD) Treatment. We also highlight some exciting new therapies coming down the pipeline that have the potential to cause big changes in MGD treatment in the near future.

“About the Sponsor”:

Santen

As a global specialized company dedicated to ophthalmology, Santen brings a 130-year history of scientific knowledge and organizational capabilities to research, development, and commercialization of pharmaceuticals, surgical and medical devices, and OTC eye-care products. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan, and its products now reach patients in more than 60 countries. Santen provides products and services to contribute to the well-being of patients, their loved ones, and consequently to society. For more information, please visit Santen's websites www.santenusa.com and www.santen.com (Japan headquarters).

Eye Eco Inc.

As a leading manufacturer of clinically proven and patented dry eye therapies, Eye Eco has helped thousands of practices across the country implement highly effective protocols for mild, moderate, and advanced MGD patients, as well as those suffering from Nocturnal Evaporative Stress. Eye Eco Inc. is California-based, locally owned, and 100% committed to developing innovations in the eye hydration field. Our goal is to bring long lasting relief to dry, irritated eyes through natural, effective products that improve the quality of patient’s lives, every single day.

The Role of Trigeminal Nerve in OSD Treatment

Shane Swatts — Fri, 16 Aug 2024 12:21:44 +0000

Interview with Laura Periman, MD from Periman Eye Institute.

The Dry Eye Master graces us with her deep knowledge of how to maximize the body’s nervous system to assist with successful dry eye therapy. She discusses the ideal patient type, dosing, and tips to maximize patient outcomes. This is an episode you can’t miss!

Heavy Lifting- Modern Treatment for Drooping Lids: TempSure Envi*, Upneeq, or Blepharoplasty

Shane Swatts — Fri, 16 Aug 2024 11:59:00 +0000

Thanks to the “Zoom Boom,” patients are aware of personal appearance now, more aware than ever before. In this episode, Dr. Mila Ioussifova discusses latest modern options for both health and aesthetics to give patients the lift they need!

Novel Dry Eye Treatment Pathways: Understanding the MOA

Shane Swatts — Fri, 16 Aug 2024 11:35:22 +0000

Novel Dry Eye Treatment Pathways: Understanding the MOA

With so many pharmaceutical treatment options, how do you decide which treatment to prescribe? From dry eye flares to chronic dry eye therapies, Dr. Doug Devries will provide his insights on how the mechanism of action (MOA) for our current and newest dry eye treatment options impacts his decision making and management.

“About the Sponsor”:

Santen

Identifying and Treating Nocturnal Evaporative Stress

Shane Swatts — Fri, 16 Aug 2024 10:59:00 +0000

Interview with Leslie O’Dell, OD, FAAO, Medical Director of Medical Optometry of America, Shrewsbury, PA. Internationally recognized Dr. Leslie O’Dell wakes us to the truth on how eye dryness can happen while we sleep. Find out how to detect and prevent nocturnal lagophthalmos and nighttime exposure.

Biologics and OSD: Why? When? How?

Shane Swatts — Fri, 16 Aug 2024 10:41:03 +0000

Interview with Hardeep Kataria, OD, FAAO, Avant Eyes Optometry, Porter Ranch, CA. Dr. Hardeep Kataria shares with us how to harness the power of biologics from the human body. Amniotic materials and blood-derived therapies are now widely available as choices for ocular surface dryness patients.

Worlds Collide: Dry Eye and Ocular Allergy / Dry Eye Juice Box

Shane Swatts — Fri, 16 Aug 2024 10:04:36 +0000

Interview with Josh Davidson, OD, FAAO from Williamson Eye Center in Baton Rouge, LA. Dr. Josh Davidson scratches below the surface of ocular surface irritation to find the connection between ocular allergies and dryness. Take away practice pearls to use during the worst of pollen seasons! Dr. Davidson also shares with us his novel approach for dry eye nutrition.

“About the Sponsor”:

Santen

Role of PF, HA, Lipids, Trehalose

Shane Swatts — Fri, 16 Aug 2024 08:47:49 +0000

Interview with Cecelia Koetting, OD, FAAO, Burcham EyeCare Center, Aurora, CO. What exactly is the difference between all those artificial tears? Dr. Koetting gives us a clear picture of the different ingredients that make certain artificial tears shine on the ocular surface. You won’t want to miss this refreshing discussion!

“About the Sponsor”: No sponsor for this episode

Guts Matter

Shane Swatts — Fri, 16 Aug 2024 08:42:52 +0000

Interview with Vitto Mena, OD, FAAO, from the Optical Academy in Clifton, New Jersey. Leaky or inflamed guts and an off-balance microbiome in the human body is linked to ocular surface dryness. Dr. Vitto Mena discusses how to maximize nutrition to improve ocular surface dryness.

“About the Sponsor”:

Eye Eco Inc.

Canadian Dry Eye: Not the Ginger

Shane Swatts — Fri, 16 Aug 2024 08:41:12 +0000

Interview with Mahnia Madan, OD. Dr. Mahnia Madan brings her knowledge of practicing in both the US and Canada to the table. This podcast is dedicated to our listeners across the border who may have questions about scope of practice and available treatments in Canada. Find out what unique options make Canada special.

“About the Sponsor”:

Santen

Kala

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of proprietary NCE development programs targeted to address unmet medical needs, including both front and back of the eye diseases.

Flipping the Model- Creating a Medical Dry Eye Center

Shane Swatts — Fri, 16 Aug 2024 08:27:59 +0000

Interview with Jason Besecker, OD from Envision Specialty EyeCare and Dry Eye Center. Dr. Besecker shares how he changed the medical model and operates a very unique medical practice in his community. Find out what’s really necessary to build a dry eye practice.

“About the Sponsor”:

Thea Pharma, Inc. is an independent pharmaceutical company specializing in the commercialization of eye care products.

Established in 2019, Thea Pharma is the United States subsidiary of Laboratoires Théa, a global leader and pioneer in ophthalmic. We are committed to serve doctors that treat the anterior segment and ocular surface conditions.

Our goal is to deliver uncompromising care that allows all stakeholders to envision the future of ophthalmic treatment with eyes wide open.

WE CAN BUILD A FUTURE FILLED WITH BETTER OUTCOMES. TOGETHER.

Our Passion for OSD

Shane Swatts — Fri, 16 Aug 2024 08:22:32 +0000

Interview with Lisa Hornick, OD and Kristyna Lensky Sipes, OD from Stanford Ranch Optometry. Meet the doctors who are helping write the story of dry eye! This powerhouse team is using their way with words to help educate doctors on the latest in treatment strategies. Find out what resources will available soon!

“About the Sponsor”:

Thea Pharma, Inc. is an independent pharmaceutical company specializing in the commercialization of eye care products.

Established in 2019, Thea Pharma is the United States subsidiary of Laboratoires Théa, a global leader and pioneer in ophthalmics. We are committed to serve doctors that treat the anterior segment and ocular surface conditions.

Our goal is to deliver uncompromising care that allows all stakeholders to envision the future of ophthalmic treatment with eyes wide open.

WE CAN BUILD A FUTURE FILLED WITH BETTER OUTCOMES. TOGETHER.

Topical Preservatives: Friend or Foe

Shane Swatts — Fri, 16 Aug 2024 08:17:48 +0000

Interview with Ahmad Fahmy, OD, from Minnesota Eye Consultants. Dr. Fahmy gives insight into the safest options for the ocular surface. Do preservative-free eyedrops really matter? This is one discussion that you won’t want to expire!

“About the Sponsor”:

Thea Pharma, Inc. is an independent pharmaceutical company specializing in the commercialization of eye care products.

Our goal is to deliver uncompromising care that allows all stakeholders to envision the future of ophthalmic treatment with eyes wide open.

WE CAN BUILD A FUTURE FILLED WITH BETTER OUTCOMES. TOGETHER.

The Impact of OSD on Glaucoma Patients

Shane Swatts — Fri, 16 Aug 2024 07:34:00 +0000

Interview with Justin Schweitzer, OD, from Vance Thompson Vision. Dr. Schweitzer reduces the pressure on how to efficiently manage glaucoma patients with ocular surface dryness. He gives up the rundown on topical eyedrops, preservatives, and surgical options to balance pressure and dryness.

“About the Sponsor”:

Thea Pharma, Inc. is an independent pharmaceutical company specializing in the commercialization of eye care products.

Our goal is to deliver uncompromising care that allows all stakeholders to envision the future of ophthalmic treatment with eyes wide open.

WE CAN BUILD A FUTURE FILLED WITH BETTER OUTCOMES. TOGETHER.

What’s Hot End of 2023 and Beyond

Shane Swatts — Fri, 16 Aug 2024 07:08:00 +0000

Episode 1 “What’s Hot End of 2023 and Beyond?" Interview with Jacob Lang, OD from Associated Eye Care. What were the newest and biggest dry eye upsets in 2023? Dr. Lang gives us the updates and discusses the future of promising clinical trials.

“About the Sponsor”:

Thea Pharma, Inc. is an independent pharmaceutical company specializing in the commercialization of eye care products.

Our goal is to deliver uncompromising care that allows all stakeholders to envision the future of ophthalmic treatment with eyes wide open.

WE CAN BUILD A FUTURE FILLED WITH BETTER OUTCOMES. TOGETHER.